Andrew Fenton - Zoetis President

ZTS -- USA Stock  

USD 124.27  1.03  0.84%

Mr. Andrew Fenton is Executive Vice President and Chief Digital and Technology Officer of the Company
Age: 54  President Since 2018      
Fenton has served as our Executive Vice President and Chief Digital and Technology Officer since December 2018, having previously served as Executive Vice President and Chief Information Officer from August 2016 to December 2018 and having joined Zoetis as Senior Vice President and CIO in 2014. From November 2013 to September 2014, Mr. Fenton was a partner and principal with EY in the Life Sciences practice supporting CIO Transformation Services, and from October 2005 to November 2013, he was Senior Vice President and CIO of Warner Chilcott. He has also held senior positions at IBM Global Services and at PricewaterhouseCoopers in the Pharmaceutical Practice.

Andrew Fenton Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Thomas FarringtonPerrigo Company plc
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Charles WagnerVertex Pharmaceuticals Incorpor
Jeffrey NeedhamPerrigo Company plc
Amit SachdevVertex Pharmaceuticals Incorpor
John WesolowskiPerrigo Company plc
Douglas McCorkleRegeneron Pharmaceuticals
Grainne QuinnPerrigo Company plc
Michael StewartPerrigo Company plc
Ian SmithVertex Pharmaceuticals Incorpor
Daniel PlewRegeneron Pharmaceuticals
John HendricksonPerrigo Company plc
Alok SonigDr Reddys Laboratories Ltd
Samiran DasDr Reddys Laboratories Ltd
James MichaudPerrigo Company plc
Ganadhish KamatDr Reddys Laboratories Ltd
Michael AbermanRegeneron Pharmaceuticals
Peter PowchikRegeneron Pharmaceuticals
Sripada ChandrasekharDr Reddys Laboratories Ltd
Jatin ShahPerrigo Company plc
Marion McCourtRegeneron Pharmaceuticals

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
See also Your Current Watchlist. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.